• Home
  • Study Details
COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

NBTXR3 With or Without Cetuximab in locally advanced head & neck squamous cell carcinoma

The purpose of this study is to find out if an investigational medication (NBTXR3) could help elderly patients with locally advanced head & neck squamous cell carcinoma who are otherwise ineligible to receive platinum-based chemotherapy. This study will help to determine the recommended dose/s of NBTXR3. The study medication is injected directly into the tumor and is activated by radiation therapy in combination with anti-PD1 therapy.

Age & Gender

  • 65 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Colette Shen
Radiation Oncology - Chapel Hill

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck, Liver, Lung, Sarcoma (bone and soft tissue), Phase 1 Trials (all cancers))

IRB Number

18-0943

ClinicalTrials.gov

NCT03589339

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research